Development of therapeutic strategies and pathogenesis analysis of Helicobacter cinaedi

2022 Fiscal Year Final Research Report

• Project/Area Number: 18K15152
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 49050:Bacteriology-related
• Research Institution: Aichi Gakuin University
• Principal Investigator: Nakashima Junko (富田純子) 愛知学院大学, 薬学部, 講師 (10454323)
• Project Period (FY): 2018-04-01 – 2023-03-31
• Keywords: 薬剤感受性 / MIC / 薬剤耐性 / 分泌装置

Outline of Final Research Achievements

The MICs of the Helicobacter cinaedi isolates were determined by the broth microdilution method. For resistant strains, mutations were detected by analyzing resistance-related genes. By comparing the amino acid sequences of the drug efflux system, we found that a certain point mutation is involved in the development of high drug resistance.
We focused on the type IV secretion system (T6SS) gene cluster for the pathogenicity of H. cinaedi. T6SS was involved in infecting host cells. Furthermore, a T6SS effector candidate protein was detected. The proteins inhibited bacterial growth.

Free Research Field

細菌学

Academic Significance and Societal Importance of the Research Achievements

ヘリコバクター・シネディ感染症の感受性試験データは、治療方針策定と薬剤耐性化の現状を把握するための重要なデータである。今後、医療施設と協力して本菌種のブレイクポイントMICを策定し、適正な抗菌薬治療の方針が定められることにより本菌種感染症の早期治療に繋がると考えられる。